You are here

FDA Clears the Randomized Portion of the Phase 2 Study of TNFerade in Pancreatic Cancer

GAITHERSBURG, Md., Feb. 11 /PRNewswire-FirstCall/ -- GenVec, Inc. (NASDAQ:GNVC) announced that it has received a letter from the U.S. Food and Drug Administration (FDA) today, which allows the company to proceed with the randomized, controlled portion of the Phase II clinical trial of TNFerade in patients with locally advanced pancreatic cancer. This clinical study is designed to assess the clinical benefit of using TNFerade in combination with standard of care treatment in patients with this disease. In October 2004, the FDA placed the TNFerade clinical program on hold due to blood clots seen in patients with esophageal cancer in a separate Phase II trial. In response, GenVec submitted data to the FDA and requested permission to move forward only with the pancreatic cancer study. Other indications that were affected (esophageal and rectal cancer) remain on clinical hold.

The 74-patient randomized, controlled portion of the Phase II study will assess the activity of TNFerade when administered concurrently with 5- flourouracil (5-FU) plus radiation followed by Gemcitabine, versus 5-FU plus radiation followed by Gemcitabine. Outcome measures will include progression- free survival at three months post-treatment, median survival, tumor resectability post-treatment, and objective tumor response.

Results of the dose-escalation portion of this study of TNFerade in patients with pancreatic cancer were presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium on January 28, 2005. The poster presentation can be viewed by accessing the following website address: http://www.genvec.com/art/download/Senzer0501_poster.pdf. The dose for the upcoming randomized trial, 4 x 10e11 pu, was shown to be generally well-tolerated. Eleven patients, in two groups, received the 4 x 10e11 pu dosage. The median survival attained by the first group (7 patients) receiving the 4 x 10e11 pu dose was reported at 16.5 months. Median survival for the second group (4 patients) receiving the 4 x 10e11 pu dose has not yet been reached. Sixty percent demonstrated tumor shrinkage greater than 25 percent (6 of 10 evaluable patients) and 20 percent demonstrated tumor shrinkage exceeding 50 percent (2 of 10 evaluable patients). Dose-related improvements in time to disease progression and rates of surgical resection post-treatment were also seen.

"We are very pleased to resume clinical testing of TNFerade in patients with pancreatic cancer and look forward to enrolling patients in this phase of the study as quickly as possible. In the meantime, we will work closely with the FDA to chart a course for the potential clinical development of other promising indications for TNFerade," said Paul D. Kessler, M.D., GenVec's executive director of clinical research.

TNFerade is an adenovector, a DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNF-alpha), an immune system protein with potent and well-documented anti-cancer effects. After direct injection into tumors, TNFerade stimulates the production of TNF-alpha in the tumor. GenVec clinical investigators have been evaluating TNFerade in combination with radiation and chemotherapy for the treatment of various cancers.

Source: GenVec Inc.

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds